Proteintech

HLA class I ABC Polyclonal Antibody

HLA class I ABC Antibody in Immunoprecipitation (IP)

FIGURE: 1 / 15

HLA class I ABC Antibody (15240-1-AP) in IP

IP result of anti-HLA class I ABC (IP:15240-1-AP, 3ug; Detection:15240-1-AP 1:500) with HepG2 cells lysate 1720ug.

HLA class I ABC Antibody in Immunocytochemistry (ICC/IF)

HLA class I ABC Antibody in Immunohistochemistry (Paraffin) (IHC (P))

HLA class I ABC Antibody in Western Blot (WB)

HLA class I ABC Antibody in Flow Cytometry (Flow)

Product Image Gallery

Product Details

15240-1-AP

Applications

Tested Dilution

Publications

Western Blot (WB)

1:500-1:3,000

View 17 publications 17 publications

Immunohistochemistry (IHC)

View 10 publications 10 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:20-1:200

Immunocytochemistry (ICC/IF)

1:10-1:100

View 7 publications 7 publications

Flow Cytometry (Flow)

0.2 µg/1x10^6 cells

Immunoprecipitation (IP)

0.5-4.0 µg

View 1 publication 1 publication

RNA Immunoprecipitation (RIP)

View 1 publication 1 publication

Miscellaneous PubMed (Misc)

View 1 publication 1 publication

Not applicable (N/A)

View 2 publications 2 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

HLA class I ABC Fusion Protein Ag7370 (28-303 aa encoded by BC003069)

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.3 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.3, with 50% glycerol

Contains

0.02% sodium azide

Storage conditions

-20°C

Shipping conditions

Wet ice (domestic); Dry ice (international)

Product Specific Information

Immunogen sequence: SMRYFFTSV SRPGRGEPRF IAVGYVDDTQ FVRFDSDAAS QKMEPRAPWI EQEGPEYWDQ ETRNMKAHSQ TDRANLGTLR GYYNQSEDGS HTIQIMYGCD VGPDGRFLRG YRQDAYDGKD YIALNEDLRS WTAADMAAQI TKRKWEAVHA AEQRRVYLEG RCVDGLRRYL ENGKETLQRT DPPKTHMTHH PISDHEATLR CWALGFYPAE ITLTWQRDGE DQTQDTELVE TRPAGDGTFQ KWAAVVVPSG EEQRYTCHVQ HEGLPKPLTL RWELSSQ (28-303 aa encoded by BC003069)

Target Information

HLA-class I major histocompatibility (MHC) antigens are intrinsic membrane glycoproteins expressed on nucleated cells and noncovalently associated with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumor defense. Human HLA-class I antigens are represented by HLA-A, HLA-B and HLA-C molecules.

HLA and MHC antibodies play a significant role in Immunopeptidomics, facilitating the identification and characterization of neoantigens through high-performance liquid chromatography coupled to tandem Mass Spectrometry.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression.

Proceedings of the National Academy of Sciences of the United States of America

Arshad N,Laurent-Rolle M,Ahmed WS,Hsu JC,Mitchell SM,Pawlak J,Sengupta D,Biswas KH,Cresswell P

Tue Jan 03 00:00:00 EST 2023

SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression.

Proceedings of the National Academy of Sciences of the United States of America

Arshad N,Laurent-Rolle M,Ahmed WS,Hsu JC,Mitchell SM,Pawlak J,Sengupta D,Biswas KH,Cresswell P

Tue Jan 03 00:00:00 EST 2023

Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.

Cancer medicine

Wu W,Chen L,Jia G,Tang Q,Han B,Xia S,Jiang Q,Liu H

Sat Jul 01 00:00:00 EDT 2023

Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.

Cancer medicine

Wu W,Chen L,Jia G,Tang Q,Han B,Xia S,Jiang Q,Liu H

Sat Jul 01 00:00:00 EDT 2023

Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma.

Frontiers in pharmacology

Li R,Yan L,Tian S,Zhao Y,Zhu Y,Wang X

Thu Feb 02 00:00:00 EST 2023

Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer.

ACS applied materials & interfaces

Guo W,Gao H,Li H,Ge S,Zhang F,Wang L,Shi H,Han A

Wed Jul 20 00:00:00 EDT 2022

Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC.

Frontiers in cell and developmental biology

Chen MY,Zeng YC,Zhao XH

Sat Jul 16 00:00:00 EDT 2022

EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.

The Journal of investigative dermatology

Xu T,Dai J,Tang L,Yang L,Si L,Sheng X,Cui C,Chi Z,Kong Y,Guo J

Fri Apr 01 00:00:00 EDT 2022

Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes.

Nature communications

Mayer RL,Verbeke R,Asselman C,Aernout I,Gul A,Eggermont D,Boucher K,Thery F,Maia TM,Demol H,Gabriels R,Martens L,Bécavin C,De Smedt SC,Vandekerckhove B,Lentacker I,Impens F

Fri Oct 14 00:00:00 EDT 2022

Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.

Gynecologic oncology

Dholakia J,Scalise CB,Katre AA,Goldsberry WN,Meza-Perez S,Randall TD,Norian LA,Novak L,Arend RC

Sat Jan 01 00:00:00 EST 2022

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

Cell

Koikawa K,Kibe S,Suizu F,Sekino N,Kim N,Manz TD,Pinch BJ,Akshinthala D,Verma A,Gaglia G,Nezu Y,Ke S,Qiu C,Ohuchida K,Oda Y,Lee TH,Wegiel B,Clohessy JG,London N,Santagata S,Wulf GM,Hidalgo M,Muthuswamy SK,Nakamura M,Gray NS,Zhou XZ,Lu KP

Thu Sep 02 00:00:00 EDT 2021

Peripheral Injection of Tim-3 Antibody Attenuates VSV Encephalitis by Enhancing MHC-I Presentation.

Frontiers in immunology

Li G,Tang L,Hou C,Wang Z,Gao Y,Dou S,Mo R,Hao Y,Gao Z,Li Y,Dong J,Zhang J,Shen B,Wang R,Han G

Wed Oct 20 00:00:00 EDT 2021

Peripheral Injection of Tim-3 Antibody Attenuates VSV Encephalitis by Enhancing MHC-I Presentation.

Frontiers in immunology

Li G,Tang L,Hou C,Wang Z,Gao Y,Dou S,Mo R,Hao Y,Gao Z,Li Y,Dong J,Zhang J,Shen B,Wang R,Han G

Wed Oct 20 00:00:00 EDT 2021

Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.

Oncogene

Li C,Yao H,Wang H,Fang JY,Xu J

Mon Feb 01 00:00:00 EST 2021

Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.

Oncogene

Li C,Yao H,Wang H,Fang JY,Xu J

Mon Feb 01 00:00:00 EST 2021

Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.

Cell death discovery

Liu W,Wang Y,Xie Y,Dai T,Fan M,Li C,Zou Y

Sat Jun 05 00:00:00 EDT 2021

Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.

Cell death discovery

Liu W,Wang Y,Xie Y,Dai T,Fan M,Li C,Zou Y

Sat Jun 05 00:00:00 EDT 2021

Immune infiltration profiling in gastric cancer and their clinical implications.

Cancer science

Ren F,Zhao Q,Zhao M,Zhu S,Liu B,Bukhari I,Zhang K,Wu W,Fu Y,Yu Y,Tang Y,Zheng P,Mi Y

Wed Sep 01 00:00:00 EDT 2021

Arecoline induces epithelial-mesenchymal transformation and promotes metastasis of oral cancer by SAA1 expression.

Cancer science

Ren H,He G,Lu Z,He Q,Li S,Huang Z,Chen Z,Cao C,Wang A

Tue Jun 01 00:00:00 EDT 2021

Hepatitis C virus modulates signal peptide peptidase to alter host protein processing.

Proceedings of the National Academy of Sciences of the United States of America

Hirano J,Yoshio S,Sakai Y,Songling L,Suzuki T,Itoh Y,Zhang H,Chen DV,Haga S,Oomori H,Kodama T,Maeda Y,Ono Y,Takahashi Y,Standley DM,Yamamoto M,Moriishi K,Moriya K,Kanto T,Takehara T,Koike K,Matsuura Y,Okamoto T

Tue Jun 01 00:00:00 EDT 2021

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.

Journal for immunotherapy of cancer

Wu SY,Xiao Y,Wei JL,Xu XE,Jin X,Hu X,Li DQ,Jiang YZ,Shao ZM

Thu Jul 01 00:00:00 EDT 2021

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.

Journal for immunotherapy of cancer

Li C,Chi H,Deng S,Wang H,Yao H,Wang Y,Chen D,Guo X,Fang JY,He F,Xu J

Sun Aug 01 00:00:00 EDT 2021

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.

Nature

Liu X,Bao X,Hu M,Chang H,Jiao M,Cheng J,Xie L,Huang Q,Li F,Li CY

Tue Dec 01 00:00:00 EST 2020

Herpes Simplex Virus Type 2 Inhibits Type I IFN Signaling Mediated by the Novel E3 Ubiquitin Protein Ligase Activity of Viral Protein ICP22.

Journal of immunology (Baltimore, Md. : 1950)

Zhang M,Fu M,Li M,Hu H,Gong S,Hu Q

Tue Sep 01 00:00:00 EDT 2020

Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/C mice.

Cancer medicine

Ma H,Wang M,Zhou Y,Yang JJ,Wang LY,Yang RH,Wen MJ,Kong L

Wed Jul 01 00:00:00 EDT 2020

Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/C mice.

Cancer medicine

Ma H,Wang M,Zhou Y,Yang JJ,Wang LY,Yang RH,Wen MJ,Kong L

Wed Jul 01 00:00:00 EDT 2020

Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity.

Cellular and molecular life sciences : CMLS

Nekoua MP,Bertin A,Sane F,Alidjinou EK,Lobert D,Trauet J,Hober C,Engelmann I,Moutairou K,Yessoufou A,Hober D

Wed Jan 01 00:00:00 EST 2020

Long Non-coding RNA LINC02195 as a Regulator of MHC I Molecules and Favorable Prognostic Marker for Head and Neck Squamous Cell Carcinoma.

Frontiers in oncology

Li H,Xiong HG,Xiao Y,Yang QC,Yang SC,Tang HC,Zhang WF,Sun ZJ

Mon Sep 28 00:00:00 EDT 2020

Long Non-coding RNA LINC02195 as a Regulator of MHC I Molecules and Favorable Prognostic Marker for Head and Neck Squamous Cell Carcinoma.

Frontiers in oncology

Li H,Xiong HG,Xiao Y,Yang QC,Yang SC,Tang HC,Zhang WF,Sun ZJ

Mon Sep 28 00:00:00 EDT 2020

Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sjögren's syndrome patients.

Clinical and experimental immunology

Shimizu T,Nakamura H,Takatani A,Umeda M,Horai Y,Kurushima S,Michitsuji T,Nakashima Y,Kawakami A

Mon Apr 01 00:00:00 EDT 2019

Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sjögren's syndrome patients.

Clinical and experimental immunology

Shimizu T,Nakamura H,Takatani A,Umeda M,Horai Y,Kurushima S,Michitsuji T,Nakashima Y,Kawakami A

Mon Apr 01 00:00:00 EDT 2019

Down-regulation of the islet-specific zinc transporter-8 (ZnT8) protects human insulinoma cells against inflammatory stress.

The Journal of biological chemistry

Merriman C,Fu D

Fri Nov 08 00:00:00 EST 2019

An ARF6-Exportin-5 axis delivers pre-miRNA cargo to tumour microvesicles.

Nature cell biology

Clancy JW,Zhang Y,Sheehan C,D'Souza-Schorey C

Mon Jul 01 00:00:00 EDT 2019

Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis.

The Journal of pathology

Guo Y,Zhang Z,Wei H,Wang J,Lv J,Zhang K,Keller ET,Yao Z,Wang Q

Sun Oct 01 00:00:00 EDT 2017

Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis.

The Journal of pathology

Guo Y,Zhang Z,Wei H,Wang J,Lv J,Zhang K,Keller ET,Yao Z,Wang Q

Sun Oct 01 00:00:00 EDT 2017

Loss of Fas expression and high expression of HLA-E promoting the immune escape of early colorectal cancer cells.

Oncology letters

Huang R,Zhang D,Li F,Xiao Z,Wu M,Shi D,Xiang P,Bao Z

Mon May 01 00:00:00 EDT 2017

HIV-1 Nef: Taking Control of Protein Trafficking.

Traffic (Copenhagen, Denmark)

Pereira EA,daSilva LL

Thu Sep 01 00:00:00 EDT 2016

Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection.

PloS one

de Carvalho JV,de Castro RO,da Silva EZ,Silveira PP,da Silva-Januário ME,Arruda E,Jamur MC,Oliver C,Aguiar RS,daSilva LL

Tue Aug 04 00:00:00 EDT 2015

Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection.

PloS one

de Carvalho JV,de Castro RO,da Silva EZ,Silveira PP,da Silva-Januário ME,Arruda E,Jamur MC,Oliver C,Aguiar RS,daSilva LL

Tue Aug 04 00:00:00 EDT 2015

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Oncotarget

Dobbin ZC,Katre AA,Steg AD,Erickson BK,Shah MM,Alvarez RD,Conner MG,Schneider D,Chen D,Landen CN

Tue Sep 30 00:00:00 EDT 2014

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Oncotarget

Dobbin ZC,Katre AA,Steg AD,Erickson BK,Shah MM,Alvarez RD,Conner MG,Schneider D,Chen D,Landen CN

Tue Sep 30 00:00:00 EDT 2014

The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.

Histopathology

Müller M,Agaimy A,Zenk J,Ettl T,Iro H,Hartmann A,Seliger B,Schwarz S

Wed May 01 00:00:00 EDT 2013

The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases.

Histopathology

Müller M,Agaimy A,Zenk J,Ettl T,Iro H,Hartmann A,Seliger B,Schwarz S

Wed May 01 00:00:00 EDT 2013

Bioinformatics

Protein Aliases: A29 protein; alpha chain of MHC class II; antigen presenting molecule; class I MHC, HLA-B antigen; epididymis secretory protein Li 83; H-2K; H-2K(d); H2-K; histocompatibility antigen; HLA -B; HLA A; HLA B-40011; HLA B44; HLA C; HLA class I antigen; HLA class I antigen HLA-B; HLA class I histocompatibility antigen C alpha chain; HLA class I histocompatibility antigen Cw-1 alpha chain; HLA class I histocompatibility antigen, A alpha chain; HLA class I histocompatibility antigen, A-30 alpha chain; HLA class I histocompatibility antigen, A-33 alpha chain; HLA class I histocompatibility antigen, A-74 alpha chain; HLA class I histocompatibility antigen, B alpha chain; HLA class I histocompatibility antigen, B-47 alpha chain; HLA class I histocompatibility antigen, B-50 alpha chain; HLA class I histocompatibility antigen, B-82 alpha chain; HLA class I histocompatibility antigen, C alpha chain; HLA class I histocompatibility antigen, Cw-15 alpha chain; HLA class I histocompatibility antigen, Cw-18 alpha chain; HLA locus; HLA molecule; HLA-A; HLA-A locus alpha 2 domain; HLA-A null; HLA-Aw33.1; HLA-B; HLA-B 1502; HLA-B alpha chain; HLA-B alpha chain (B*2706); HLA-B alpha chain (B*5002); HLA-B alpha-chain; HLA-B35; HLA-B35 antigen; HLA-Bw50 antigen; HLA-C; HLA-C alpha chain; HLA-C alpha chain (HLA-Cw*15v); HLA-C alpha chain for Cw*18GB; HLA-C alpha-chain; HLA-C antigen; HLA-Cw; HLA-Cw*04GB; HLA-Cw*1702; HLA-Cw*18GB; HLA-Cw-1503; Human leukocyte antigen A; Human leukocyte antigen B; Human leukocyte antigen C; human leukocyte antigen-C alpha chain; hypothetical protein; lecocyte antigen B; leucocyte antigen A; Leukocyte Antigen; leukocyte antigen C; leukocyte antigen class I-A; leukocyte antigen class I-B; Leukoocyte Antigen; lymphocyte antigen; major histocompatability complex B antigen; major histocompatibility antigen HLA-C; MCH class I antigen; MGC184092; MGC7052; MHC 1; MHC antigen; MHC clas I antigen; MHC Class 1; MHC class 1 antigen; MHC class I; MHC class I alpha chain; MHC class I anitgen; MHC class I anti; MHC Class I antigen; MHC class I antigen A*30; MHC class I antigen A*33; MHC class I antigen A*74; MHC class I antigen B*47; MHC class I antigen B*50; MHC class I antigen B*82; MHC class I antigen Cw*15; MHC class I antigen Cw*18; MHC class I antigen GN00104; MHC class I antigen heavy chain; MHC class I antigen heavy chain HLA-C; MHC class I antigen HLA-A heavy chain; MHC class I antigen HLA-A33; MHC class I antigen HLA-B alpha chain; MHC class I antigen HLA-B heavy chain; MHC class I antigen null protein; MHC class I antigen SHCHA; MHC class I antigene; MHC class I histocompatibility antigen; MHC class I human leukocyte antigen; MHC class I molecule; MHC class I protein; MHC class II antigen; MHC class l antigen; MHC classI antigen; MHC HLA-ABC; MHC HLA-B cell surface glycoprotein; MHC HLA-B transmembrane glycoprotein; MHC HLA-B27-HS; MHC HLA-B27d; MHC HLA-B39N; MHC I HLA; MHC1; surface antigen; truncated class I antigen; truncated MHC class I antigen

View more View less

Gene Aliases: AS; Aw-33; Aw-74; B-4901; B-5001; Bw-47; Bw-50; D6S204; HEL-S-83; HLA-A; HLA-A11; HLA-A33; HLA-B; HLA-B*45ZJ; HLA-B-3506; HLA-B-3905; HLA-B-5502; HLA-B-5602; HLA-B15; HLA-B39; HLA-B49; HLA-B50; HLA-B55; HLA-B59; HLA-B61; HLA-C; HLA-Cw; HLA-DQB1; HLA-DRB1; HLA-JY3; HLAA; HLAB; HLAC; HLC-C; MHC; PSORS1; SPDA1

View more View less

UniProt ID: (Human) Q9TQM6, (Human) Q31603, (Human) Q29990

View more View less

Entrez Gene ID: (Human) 3105, (Human) 3106, (Human) 3107

View more View less

Function(s)

protein binding beta-2-microglobulin binding peptide antigen binding poly(A) RNA binding antigen binding major histocompatibility complex protein

Process(es)

antigen processing and presentation of peptide antigen via MHC class I antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent viral process antigen processing and presentation regulation of immune response interferon-gamma-mediated signaling pathway type I interferon signaling pathway

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

HLA class I ABC Polyclonal Antibody

HLA class I ABC Antibody (15240-1-AP) in IP

Product Details

15240-1-AP

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunocytochemistry (ICC/IF)

Flow Cytometry (Flow)

Immunoprecipitation (IP)

RNA Immunoprecipitation (RIP)

Miscellaneous PubMed (Misc)

Not applicable (N/A)

Species Reactivity

Published species

Host/Isotype

Class

Type

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!